Aldosterone Hypothesis for Cognitive Impairment in Diabetes Mellitus

Abstract

Increased plasma aldosterone concentration is significantly associated with dementia, which is accentuated by diabetes mellitus (DM). Angiotensin II (AngII) deteriorates cognitive function through neuronal degradation. Lipoproteins, a major source of cholesterol for aldosterone biosynthesis, undergo glycoxidative modifications in the presence of hyperglycemia. We hypothesize that there would be a pathophysiological link between diabetically-modified lipoproteins, angiotensin II, and increased plasma aldosterone concentration for induction of cognitive impairment. Glycoxidized lipoproteins produce significantly more aldosterone from AngII-sensitized adrenocortical cells compared to their native counterparts. The elucidation of signaling mechanisms revealed that modified lipoproteins follow the similar signaling mechanism like AngII for adrenocortical aldosterone release via ERK1/2 and Janus kinase-2 (Jak-2)-mediated pathways. The enhanced aldosterone release from AngII-sensitized adrenocortical cells induced by glycoxidatively modified lipoproteins may play a crucial role in cognitive dysfunction in diabetic individuals along with AngII via a prevailing mode of signaling cascade involving ERK1/2- and Jak-2-dependent pathways.

Key words

glycoxidative modification - dementia - angiotensin II - aldosterone - lipoproteins

• References

• 1 Zuliani G, Cavalieri M, Galvani M, Volpato S, Cherubini A, Bandinelli S, Corsi AM, Lauretani F, Guralnik JM, Fellin R, Ferrucci L. Relationship between low levels of high-density lipoprotein cholesterol and dementia in the elderly. The InChianti study. J Gerontol A-Biol 2010; 65: 559-564
• 2 Funder JW. Primary aldosteronism: New answers, new questions. Horm Metab Res 2015; 47: 935-940
• 3 Lichtenauer UD, Gerum S, Asbach E, Manolopoulou J, Fourkiotis V, Quinkler M, Bidlingmaier M, Reincke M. The Clinical value of salivary aldosterone in diagnosis and follow-up of primary aldosteronism. Horm Metab Res 2016; 48: 638-643
• 4 Korah HE, Scholl UI. An Update on familial hyperaldosteronism. Horm Metab Res 2015; 47: 941-946
• 5 Zennaro MC, Fernandes-Rosa F, Boulkroun S, Jeunemaitre X. Bilateral idiopathic adrenal hyperplasia: Genetics and beyond. Horm Metab Res 2015; 47: 947-952
• 6 Moors M, Williams TA, Deinum J, Eisenhofer G, Reincke M, Lenders JW. Steroid hormone production in patients with aldosterone producing adenomas. Horm Metab Res 2015; 47: 967-972
• 7 Catena C, Colussi G, Brosolo G, Novello M, Sechi LA. Aldosterone and left ventricular remodeling. Horm Metab Res 2015; 47: 981-986
• 8 Prejbisz A, Warchol-Celinska E, Lenders JW, Januszewicz A. Cardiovascular risk in primary hyperaldosteronism. Horm Metab Res 2015; 47: 973-980
• 9 Asbach E, Bekeran M, Reincke M. Parathyroid gland function in primary aldosteronism. Horm Metab Res 2015; 47: 994-999
• 10 Viola A, Monticone S, Burrello J, Buffolo F, Lucchiari M, Rabbia F, Williams TA, Veglio F, Mengozzi G, Mulatero P. Renin and aldosterone measurements in the management of arterial hypertension. Horm Metab Res 2015; 47: 418-426
• 11 Bundalo M, Zivkovic M, Tepavcevic S, Culafic T, Koricanac G, Stankovic A. Fructose-Rich diet-induced changes in the expression of the renin angiotensin system molecules in the heart of ovariectomized female rats could be reversed by estradiol. Horm Metab Res 2015; 47: 521-527
• 12 Yagi S, Akaike M, Aihara K, Iwase T, Yoshida S, Sumitomo-Ueda Y, Ikeda Y, Ishikawa K, Matsumoto T, Sata M. High plasma aldosterone concentration is a novel risk factor of cognitive impairment in patients with hypertension. Hypertension Res 2011; 34: 74-78
• 13 Mogi M, Iwanami J, Horiuchi M. Roles of brain angiotensin II in cognitive function and dementia. Int J Hypertension 2012; 169649
• 14 Saha S, Willenberg HS, Bornstein SR, Graessler J, Kopprasch S. Diabetic lipoproteins and adrenal aldosterone synthesis–a possible pathophysiological link?. Horm Metab Res 2012; 44: 239-244
• 15 Li L, Willets RS, Polidori MC, Stahl W, Nelles G, Sies H, Griffiths HR. Oxidative LDL modification is increased in vascular dementia and is inversely associated with cognitive performance. Free Radical Res 2010; 44: 241-248
• 16 Rodrigue KM, Rieck JR, Kennedy KM, Devous Sr. MD, Diaz-Arrastia R, Park DC. Risk factors for beta-amyloid deposition in healthy aging: Vascular and genetic effects. JAMA Neurol 2013; 70: 600-606
• 17 Saha S, Bornstein SR, Graessler J, Kopprasch S. Crosstalk between glycoxidative modification of low-density lipoprotein, angiotensin ii-sensitization, and adrenocortical aldosterone release. Horm Metab Res 2015; 47: 855-860